An Emerging Company
GluMetrics is a medical device company applying patented technology to create tools that enable clinicians to successfully implement a new care paradigm for critically ill patients.
Scientific evidence confirms that dramatic improvements in the clinical outcome of hospitalized Intensive Care Unit (ICU) patients can result from tight therapeutic control of blood glucose to normal ranges. These studies indicate that glycemic control of ICU patients may reduce mortality by as much as 40%1 and significantly lower complication rates.
GluMetrics is developing the GluCath® intravascular continuous glucose monitor* to accurately, conveniently and continuously measure blood sugar. The system is being specifically designed to address the challenging needs of the ICU environment.
GluMetrics has established a significant intellectual property position through the discovery, acquisition and/or licensing of key patents relating to the composition and preparation of fluorescent chemistry and polymer compounds. All assets, know-how, IP and trade secrets of Diametrics Medical, Inc. relating to the continuous intravascular measurement of blood constituents including glucose were acquired in July 2006 through the acquisition of TGC Research, Ltd. GluMetrics also wishes to acknowledge support from the Industry University Cooperative Research Program of the University of California.
GluMetrics, through the development of the GluCath system, will provide hospitals with affordable technology to realize the clinical and financial benefits of glycemic control.
GluMetrics, Inc. is a privately-held corporation not listed with the public markets and, as such, is not available to individual investors at this time.
*CAUTION–Investigational Device. Limited by United States law to investigational use.
1. Van den Berghe G, et al. Intensive Insulin Therapy in Critically Ill Patients. N Engl J Med. 2001;345(19):1359―67.